- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04119947
Single Ascending Oral Doses of SY-009 in Healthy Subjects
Evaluation of Safety, Tolerance and Pharmacokinetics/Pharmacodynamics of SY-009 Capsules After Single Dose Incremental Oral Administration in Healthy Subjects
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- China-Japan Friendship Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1、healthy subject:determined by medical history, physical examination, Imaging examination, abdominal B-mode ultrasonography (include liver, gallbladder, pancreas, spleen and kidney), electrocardiogram and laboratory tests. Test results within the normal range for the population or investigator site, or with abnormalities deemed clinically insignificant by the investigator; 2、Gender: Male and female, gender balance; 3、Age: 18-65 years old (including the boundary values); 4、Weight ≥50kg and 19.0kg/m2≤BMI≤28.0kg/m2 [BMI=body weight(kg)/height 2 (m2); 5、fasting plasm glucose (FPG): 3.9-6.1mmol/L (excluding the boundary valuses); 6、2h postprandial plasma giucose(2hPPG)<7.8mmol/L; 7、glycosylated hemoglobin (HbA1c) <5.7%;
8、have venous access sufficient to allow blood sampling as per the protocol;
9、Subjects must have informed consent before the study and sign a written informed consent form voluntarily;
10、Subjects can communicate well with investigator and complete the study according to the protocol.
Exclusion Criteria:
- are investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
- within 3 months prior to screening, complete or withdraw a clinical study, or are currently conducting a clinical study. Or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
- have previously completed or withdrawn from this study.
- have known allergies to compounds related to SY-009 capsules or its adjuvants,or allergic constitution/allergic history, or SGLT1 or SGLT2 inhibitors taken in the past one year.
- with cardiovascular diseases, respiratory diseases, gastrointestinal diseases, endocrine diseases, blood system diseases, nervous system diseases, disease status can significantly change the absorption, distribution, metabolism and excretion of experimental drugs, or taking experimental drugs will increase the risk of subjects.
- In the past five years, there has been a history of drug abuse or drug abuse tests positive.
- show evidence or test positive on any of the following: hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCV), Treponema pallidum antibody (S-TP), HIV (HIV1 + 2) antibody.
- Blood donation or massive blood loss exceeding 400 mL in the first three months prior to screening, or surgical operation and blood or blood component transfusion within the first four weeks prior to screening, or have history of fainting or needle fainting.
- Subjects who have an average weekly alcohol intake that exceeds and 14 units per week (1 unit = 360 mL beer, 45 mL alcohol content of 40% spirits or 150 mL wine) or subjects unwilling to stop alcohol consumption 24 hours prior to dosing until the completion of each inpatient study period.
- consume more than 5 cigarettes per day or the equivalent, or are unable or unwilling to refrain from nicotine during the study.
- intend to use any medicine or health care product within 14 days prior to dosing or during the study.
- subjects not agree to use reliable contraceptive methods (hormones or barriers or abstinence) during the study period and at least 1 month after administration.
- women were positive for blood pregnancy test within 24 hours prior to enrollment.
- pregnant or lactating women.
- Have special dietary requirements,and impossible to comply with the unified diet.
- Unable to stop eating chocolate, any caffeine-containing food or beverage (such as pitaya, grapefruit, orange juice, mango, etc.) 48 hours before administration and during the study.
- Within 30 days prior to screening, any drugs that inhibit or induce drug metabolic enzymes in the liver (e.g. barbiturates, carbamazepine, phenytoin sodium, glucocorticoids, omeprazole, SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative hypnotics, verapamil, fluoroquinolones, antihistamines) were used.
- in the opinion of the investigator , are unsuitable for inclusion in the study,or subjects withdraw informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SY-009 dose 1
A single dose of SY-009 (0.5-40mg) taken orally.
|
The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) .
Doses will be escalated in subsequent dosing process, after appropriate review of safety data.
The subsequent planned doses are 2,5, 10, 20, 40mg successively.
The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
|
Experimental: SY-009 dose 2
A single dose of SY-009 (0.5-40mg) taken orally.
|
The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) .
Doses will be escalated in subsequent dosing process, after appropriate review of safety data.
The subsequent planned doses are 2,5, 10, 20, 40mg successively.
The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
|
Experimental: SY-009 dose 3
A single dose of SY-009 (0.5-40mg) taken orally.
|
The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) .
Doses will be escalated in subsequent dosing process, after appropriate review of safety data.
The subsequent planned doses are 2,5, 10, 20, 40mg successively.
The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
|
Experimental: SY-009 dose 4
A single dose of SY-009 (0.5-40mg) taken orally.
|
The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) .
Doses will be escalated in subsequent dosing process, after appropriate review of safety data.
The subsequent planned doses are 2,5, 10, 20, 40mg successively.
The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
|
Experimental: SY-009 dose 5
A single dose of SY-009 (0.5-40mg) taken orally.
|
The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) .
Doses will be escalated in subsequent dosing process, after appropriate review of safety data.
The subsequent planned doses are 2,5, 10, 20, 40mg successively.
The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
|
Experimental: SY-009 dose 6
A single dose of SY-009 (0.5-40mg) taken orally.
|
The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) .
Doses will be escalated in subsequent dosing process, after appropriate review of safety data.
The subsequent planned doses are 2,5, 10, 20, 40mg successively.
The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
|
Placebo Comparator: SY-009 matching placebo
from 2-40mg
|
The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) .
Doses will be escalated in subsequent dosing process, after appropriate review of safety data.
The subsequent planned doses are 2,5, 10, 20, 40mg successively.
The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Safety and tolerance of SY-009,Collecting Number of subjects with adverse events as assessed by CTCAE V5.0
Time Frame: 7 Days
|
Number of subjects with adverse events, major adverse events, serious adverse events, pregnancy events, abnormal Laboratory Values, abnormal vital signs, Abnormal physical examination, Abnormal ECG data.
|
7 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
area under curve (AUC) of SY-009 following oral administration of single ascending dose
Time Frame: 3 Days
|
to measure the study drug concentration in blood samples to be collected after drug administration.
|
3 Days
|
Cmax of SY-009 following oral administration of single ascending dose
Time Frame: 3 Days
|
to measure the study drug concentration in blood samples to be collected after drug administration.
|
3 Days
|
T1/2 of SY-009 following oral administration of single ascending dose
Time Frame: 3 Days
|
to measure the study drug concentration in blood samples to be collected after drug administration.
|
3 Days
|
CL/F (Clearance rectified) of SY-009 following oral administration of single ascending dose
Time Frame: 3 Days
|
to measure the study drug concentration in blood samples to be collected after drug administration.
|
3 Days
|
glucose levels following single dose of SY-009
Time Frame: 3 Days
|
FPG AUC
|
3 Days
|
insulin secretion following single dose of SY-009
Time Frame: 3 Days
|
insulin changes
|
3 Days
|
C-peptide secretion following single dose of SY-009
Time Frame: 3 Days
|
C-peptide change
|
3 Days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jingtong Li, Doctor, China-Japan Friendship Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SY009001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
Clinical Trials on SY-009
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Completed
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Not yet recruiting
-
Shouyao Holdings (Beijing) Co. LTDRecruitingNon-Small Cell Lung Cancer | Solid Tumor | Medullary Thyroid CancerChina
-
Alexza Pharmaceuticals, Inc.Completed
-
Shouyao Holdings (Beijing) Co. LTDRecruitingNon-Small Cell Lung CancerChina
-
Shouyao Holdings (Beijing) Co. LTDRecruitingAdvanced Solid TumorChina
-
Shouyao Holdings (Beijing) Co. LTDRecruitingAdvanced Solid TumorChina
-
Shouyao Holdings (Beijing) Co. LTDRecruiting
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.CompletedType 2 Diabetes MellitusChina
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Completed